Nordic healthcare and biotech growth capital investor KDev Investments, jointly owned by Karolinska Development and Rosetta Capital, has sold its stake in Swedish pharmaceutical research business Inhalation Sciences to Råsunda Förvaltning.
With the support of Råsunda Förvaltning, Inhalation Sciences will look to expand internationally. Meanwhile, KDev retains an interest in the company through an earn-out agreement.
Inhalation Sciences is a pharmaceutical research and drug development company in the field of inhalation drugs.
It also operates PreciseInhale, a service that provides lung data for pharmaceutical, biotechnology and industrial customers. The company was founded in 2004 and is based in Stockholm.
Karolinska Development – Jim Van Heusden (CEO).
Inhalation Sciences – Fredrik Sjövall (CEO); Per Gerde (founder).
Transaction marks first exit completed by Omnes from its Omnes Croissance 4 vehicle, coming two years after investment
Catch up on essential features from this past week with our round-up of industry analysis
French branch of pan-European GP 21 Partners intends to take the company private upon the deal's completion
French GP exits its stake in the German forzen foods manufacturer after a four-year holding period